DCOY Decoy Therapeutics Inc.
Price Chart
Executive Summary
Decoy Therapeutics Inc. (DCOY) has regained compliance with Nasdaq's $1.00 minimum bid price requirement after implementing a reverse stock split and trading above $1.00 for 10 consecutive business days, with the Nasdaq Hearings Panel confirming compliance on March 31, 2026. However, the company will remain under a Mandatory Panel Monitor until March 31, 2027, during which any future noncompliance could lead to delisting.
Actionable Insight
While the immediate delisting threat has been resolved, traders should monitor DCOY's stock price closely throughout 2026-2027 as any drop below $1.00 during the Mandatory Panel Monitor period will trigger automatic delisting proceedings. The company's small $3M market cap and history of noncompliance suggest ongoing financial instability despite this temporary reprieve.
Key Facts
- Received Nasdaq noncompliance notice on December 31, 2025, for failing to maintain $1.00 minimum bid price for 30 consecutive days
- Implemented a reverse stock split effective March 6, 2026, began trading on split-adjusted basis March 9, 2026
- Granted exception period until March 20, 2026, to regain compliance after hearing with Nasdaq Hearings Panel on February 6, 2026
- Stock closed at $7.47 per share on March 20, 2026, demonstrating compliance by trading above $1.00 for 10 consecutive business days
- Nasdaq Hearings Panel confirmed compliance with all listing requirements on March 31, 2026
- Company subject to Mandatory Panel Monitor until March 31, 2027, with automatic delisting proceedings if it falls below $1.00 during this period
Financial Impact
The reverse stock split adjusted share count and increased share price from below $1.00 to $7.47, but no financial statement impact or fundraising was disclosed
Risk Factors
- Automatic delisting if share price falls below $1.00 at any point during the one-year Mandatory Panel Monitor period ending March 31, 2027
- History of noncompliance suggests fundamental business challenges that the reverse stock split does not address
- Small $3M market cap indicates high vulnerability to market fluctuations and potential liquidity issues
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-139145 |
| Document: dcoy-ex99_1.htm | 0001193125-26-139145 |
| Document: 0001193125-26-139145-index-headers.html | 0001193125-26-139145 |
| Document: 0001193125-26-139145-index.html | 0001193125-26-139145 |
| Document: 0001193125-26-139145.txt | 0001193125-26-139145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
DEFA14A
| $6.71 $6.61 | ▼ −1.49% | ▲ +1.11% | $6.01 (−10.43%) |
|
Apr 30, 2026
6w ago
|
10-K/A
| $6.05 $5.90 | ▼ −2.48% | ▼ −2.70% | $6.01 (−0.66%) |
|
Apr 2, 2026
10w ago
|
8-K
| $5.80 $5.89 | ▲ +1.55% | ▲ +1.08% | $6.01 (+3.62%) |
|
Mar 5, 2026
14w ago
|
8-K
| $7.00 $7.58 | ▲ +8.40% | ▲ +9.72% | $6.01 (−14.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access